Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003120 · ClinicalTrials.gov registry record · Phase 3
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 308
- Enrollment target
NCT00003120 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 308 participants.
The verdict
NCT00003120, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 308 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known whether giving paclitaxel for a shorter period of time is as effective as a standard course of treatment for advanced ovarian cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel given for 3 months with that of paclitaxel given for 12 months in treating patients who have stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer.
Interventions
- DRUG paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 1997-11 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003120
The ClinicalTrials.gov registry entry for NCT00003120 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which paclitaxel is the first listed.
NCT00003120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003120 about?
NCT00003120 is a clinical study titled "S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known whether giving paclitaxel for a shorter period of time is as effective as a standard course of treatment for advanced ovarian cancer. PURPOSE: Randomized phas...
What is the current status of trial NCT00003120?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 308 participants. The study started on 1997-11. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00003120?
The interventions under investigation include: paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00003120?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.